Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $59.20 Consensus Price Target from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have received a consensus rating of "Buy" from the eight research firms that are presently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $59.20.

ARCT has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the stock a "buy" rating in a research note on Monday, March 10th. Canaccord Genuity Group lowered their price objective on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. Wells Fargo & Company decreased their price target on Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Finally, HC Wainwright reissued a "buy" rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a research note on Thursday, April 10th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Byrne Asset Management LLC increased its stake in shares of Arcturus Therapeutics by 89.8% in the first quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 1,365 shares during the last quarter. Virtus ETF Advisers LLC raised its stake in shares of Arcturus Therapeutics by 38.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock worth $69,000 after purchasing an additional 1,132 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Arcturus Therapeutics during the 4th quarter valued at about $71,000. National Bank of Canada FI increased its holdings in Arcturus Therapeutics by 639.6% in the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company's stock worth $94,000 after buying an additional 4,784 shares during the last quarter. Finally, Kennedy Capital Management LLC lifted its stake in Arcturus Therapeutics by 22.7% in the fourth quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company's stock valued at $186,000 after acquiring an additional 2,036 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company's stock.

Arcturus Therapeutics Trading Up 2.6 %

Arcturus Therapeutics stock traded up $0.33 during midday trading on Tuesday, reaching $12.83. 240,286 shares of the stock traded hands, compared to its average volume of 451,511. Arcturus Therapeutics has a fifty-two week low of $8.04 and a fifty-two week high of $45.00. The firm has a market cap of $347.96 million, a price-to-earnings ratio of -5.78 and a beta of 3.41. The firm has a fifty day moving average price of $12.41 and a two-hundred day moving average price of $15.86.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The business had revenue of $22.77 million for the quarter, compared to analyst estimates of $44.64 million. Analysts anticipate that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.